Serum NT-proBNP and TUG1 as novel biomarkers for elderly hypertensive patients with heart failure with preserved ejection fraction

被引:13
|
作者
Zhang, Shuang [1 ]
Jin, Rize [1 ]
Li, Bi [1 ]
机构
[1] Jinzhou Med Univ, Ultrason Dept, Affiliated Hosp 1, 2 Sect,5 Renmin St, Jinzhou 121000, Liaoning, Peoples R China
关键词
heart failure with preserved ejection fraction; N-terminal pro-brain natriuretic peptide; taurine upregulated gene 1; LONG NONCODING RNA; BRAIN NATRIURETIC PEPTIDE;
D O I
10.3892/etm.2021.9874
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Patients with heart failure with preserved ejection fraction (HFPEF) account for similar to 50% of all cases of heart failure and their clinical prognosis is poor. The present study attempted to investigate the diagnostic value of circulating long non-coding RNA taurine upregulated gene 1 (TUG1) for HFPEF in subjects with hypertension. Between January 2017 and January 2019, 80 aged/elderly hypertensive patients with or without HFPEF were recruited for the present study. The concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the serum was measured using ELISA and TUG1 expression levels were determined using reverse transcription-quantitative PCR. Echocardiography was used for the determination of cardiac function. The results indicated that the levels of NT-proBNP and TUG1 were increased in the serum of hypertensive patients with HFPEF. Pearson analysis demonstrated that NT-proBNP and TUG1 were positively correlated with the left atrial diameter and negatively correlated with the ratio of the peak flow velocity in the early diastolic phase to the peak flow velocity in the late diastolic phase. In addition, a positive correlation was confirmed between TUG1 and NT-proBNP levels. Receiver operating characteristic curve analysis demonstrated that TUG1 and NT-proBNP were useful biomarkers for the diagnosis of HFPEF. In conclusion, it was observed that NT-proBNP and TUG1 were increased in the serum of hypertensive patients with HFPEF. Furthermore, TUG1 and NT-proBNP were indicated to be useful plasma biomarkers for the diagnosis of HFPEF.
引用
下载
收藏
页数:6
相关论文
共 50 条
  • [11] Clinical characteristics and outcomes of patients hospitalized with heart failure with preserved ejection fraction and low NT-proBNP levels
    Chen, Yu-Yi
    Liang, Lin
    Tian, Peng-Chao
    Feng, Jia-Yu
    Huang, Li-Yan
    Huang, Bo-Ping
    Zhao, Xue-Mei
    Wu, Yi-Hang
    Wang, Jing
    Guan, Jing-Yuan
    Li, Xin-Qing
    Zhang, Jian
    Zhang, Yu-Hui
    MEDICINE, 2023, 102 (47) : E36351
  • [12] C-reactive protein and NT-proBNP for predicting mortality in patients with heart failure with preserved ejection fraction
    Koller, L.
    Kleber, M. E.
    Goliasch, G.
    Sulzgruber, P.
    Scharnagl, H.
    Silbernagel, G.
    Grammer, T.
    Pilz, S.
    Maerz, W.
    Niessner, A.
    EUROPEAN HEART JOURNAL, 2014, 35 : 871 - 871
  • [13] Rising NT-probnp Levels Are Associated With Reduced Survival in Patients With Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Reduced Ejection Fraction (HFrEF)
    Poonacha, Thejaswi
    Sahni, Nishant
    CIRCULATION, 2015, 132
  • [14] NT-proBNP for functional capacity assessment in patients with heart failure with reduced ejection fraction
    Daniel Gomes, D.
    Cunha, G.
    Ferreira, J.
    Maltes, S.
    Rocha, B.
    Albuquerque, F.
    Paiva, M.
    Santos, R.
    Gama, F.
    Freitas, P.
    Moreno, L.
    Durazzo, A.
    Mendes, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 80 - 81
  • [15] NT-proBNP predicts impaired myocardial function in newly diagnosed hypertensive patients with preserved ejection fraction
    Sahin, Durmus Yildiray
    Gur, Mustafa
    Elbasan, Zafer
    Kirim, Sinan
    Ucar, Hakan
    Seker, Taner
    Kaypakli, Onur
    Uysal, Onur Kadir
    Kivrak, Ali
    Koyunsever, Nermin Yildiz
    Akilli, Rabia Eker
    Cayli, Murat
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2014, 36 (05) : 289 - 294
  • [16] NT-proBNP After Discharge in Patients With Decompensated Heart Failure and Preserved Left Ventricle Ejection Fraction: The NICE Study
    Figal, Domingo Pascual
    Navarro, Adrian Gallego
    Pacheco, Javier E. Blanco
    Martinez-Tovar, Maria
    Vicente, Alvaro Hernandez
    Selle, Manuel Martinez
    Gonzalez, Eduard Sole
    Fernandez, Pedro Luis Sanchez
    Pavia, Pablo Garcia
    Roman, Alfonso Varela
    Jimenez, Juan Fco. Delgado
    Perez, Alejandro Riquelme
    Velasco, Jose A. Noguera
    Llanos, Jordi Ordonez
    Genis, Antoni Bayes
    CIRCULATION, 2023, 148
  • [17] Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
    Podzolkov, V., I
    Dragomiretskaya, N. A.
    Tolmacheva, A., V
    Shvedov, I. I.
    Ivannikov, A. A.
    Yu, Akyol, V
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2023, 19 (04) : 310 - 319
  • [18] NT-proBNP - a marker of coronary artery disease in patients with preserved ejection fraction
    Tasheva, R.
    Grigorov, M.
    Vitlianova, K.
    EUROPEAN HEART JOURNAL, 2016, 37 : 391 - 391
  • [19] Novel Biomarkers in Heart Failure with Preserved Ejection Fraction
    Shah, Kevin S.
    Maisel, Alan S.
    HEART FAILURE CLINICS, 2014, 10 (03) : 471 - +
  • [20] Heart failure with preserved ejection fraction, atrial fibrillation, and increased NT-proBNP levels An emergent clinical dilemma
    Turkoglu, Ebru Ipek
    Kircicegi Cicekdag, Emine Cigdem
    HERZ, 2021, 46 : 191 - 197